Loading...
Regulatory Review
Waiting for Godot (and FDA on Pharmacogenomics Guidance)

Next CDISC Survey to Reveal Pharma's Tech Progress

Regulatory News and Information from Around the Web

   Thursday, Sep 30, 2004 Archives Bio-IT World News Bulletin Subscribe Advertising

Overcome the business, technology, regulatory and legal challenges associated with organizing data in a way that enables these assets to be referenced and utilized over time. Learn more about data rationalization of legacy systems, conversion of records to a technology neutral format, physical media degradation and technology obsolescence, as well as workflows and record lifecycle management processes – from record creation through destruction. For more information on how the IBM Corporate Information Asset Manager can help you, visit us at:  http://www.ibm.com/industries/lifesciences/regegf

Waiting for Godot (and FDA on Pharmacogenomics Guidance)

By John Russell, Bio-IT World


Throughout the summer, the industry had been expecting updated guidance from the FDA on the use of pharmacogenomics data. Now, the FDA says the guidance will be issued next month (October), but many industry executives aren't hopeful the guidance will come soon or be substantial.


"I can just tell you our interaction with FDA to date on these issues. First off, it's a great white paper critical initiative [but] they've got no money for this initiative until 2006. It just hasn't been appropriated yet," said Michael French, chief business officer, Entelos, a systems biology company doing disease modeling and biomarker identification.


French's comments came during a discussion of regulatory affairs at IBC's Implementing Systems Biology conference held in Boston last week, co-located with the Chip-to-Hits exhibition and conference. Not surprisingly, the development and use of biomarkers was a key topic at the meeting. 


"What we're hearing from our customers is that they're apprehensive about what might be read into their data sets if they turn over their whole data sets to the FDA," said Melissa Cline, senior scientist for Affymetrix. "They talk about turning over to the FDA whole systems of multifaceted data sets. One question is how to make this useful for practitioners without incurring a risk of surprises at the regulatory level."

    Read More . . .


Featured Events
CBI's 7th Original Forum on -- Customer Relationship Management (CRM) for the Bio/Pharmaceutical Industry - October 27-28, New York

Molecular Diagnostics, November 18 -19, 2004 Arlington, VA
 
2004 Pharma IT Compliance Workshops, November 15-19, 2004, Philadelphia, PA

Bio-IT World Conference & Expo - May 17 - 19, 2005, Boston, MA
 
Would you like to see your conference or event listed here? Contact Gina Bajenaru at gina_bajenaru@bio-itworld.com for more information.


Next CDISC Survey to Reveal Pharma's Tech Progress
By Mark Uehling, Bio-IT World

What do we know and how do we know it? Is electronic data capture (EDC) sweeping through the industry or crawling?

When it comes to measuring the adoption of technology for clinical trials, Becky Kush has the most reliable numbers available to the industry. (Consultants may be privy to actual - not self-reported - use of software in clinical trials on a company-specific basis.) President of CDISC, the Clinical Data Interchange Standards Consortium, Kush has embarked on another survey. This is a successor to the survey that was for years developed with CenterWatch, so historical comparisons will be possible with some questions. There won't be any vendor-specific questions this year, however.

"We're focusing more on the standards," Kush says. No surprise. She has long been spearheading a drive for CDISC standards, triangulating the needs and coordinating the agendas of the sponsor community, the vendor community, and the FDA. Henry Kissinger? Colin Powell? They should call up Kush and see if she teaches master classes.

Sample questions from the survey include: Which of the six available CDISC data models is your organization adopting? What are the expected benefits from CDISC models? Is the use of wireless/mobile technology permitted at your site? Do your trials use "e-source," entering data directly into an electronic device? Does your site do patient recruitment via the Internet? Does your site use electronic medical records?    Read More . . .

Regulatory News and Information from Around the Web

FDA Responds to Vermont Lawsuit on Drug Importation from Canada


Guidance on Clinical Trial Holds for Investigator Misconduct


Aventis Fined Over Manufacturing Issues


Walcoff Appointed Associate FDA Commissioner for External Relations


Proposal Aimed at Reducing Mad Cow Risk


USDA, FDA and DHS Sign to Make Food Supply More Secure



Featured Events

Upcoming Industry Events

CBI's 7th Original Forum on -- Customer Relationship Management (CRM) for the Bio/Pharmaceutical Industry, October 27-28, New York
Customer relationship management has become a critical component to the success of every pharmaceutical company.  Return on investment is obviously a key issue when designating resources and deploying a CRM strategy. The 2004 forum brings together industry experts to share
actual experiences and case studies on their challenges and successes in developing a customer focused strategy. For more information call 800-817-8601 or visit http://www.crmconferences.com/

Molecular Diagnostics, November 18 -19, 2004 Arlington, VA
Attend CBI's Molecular Diagnostics to hear perspectives from all players in this field and understand keys to success in this market. Featuring an FDA Keynote Address from Steven Gutman, MD, Director, Office of In Vitro Diagnostic, Device, Evaluation and Safety, Center for Device Evaluation and Radiological Health, U.S. Food & Drug Administration. Hear case studies from companies who have successfully navigated these hurdles including: Abbott Molecular Diagnostics, Digene, Genzyme Genetics, Lilly Research Labs For more information please contact the Center for Business Intelligence by phone at 1-800-817-8601or by e-mail at cbireg@cbinet.com. Visit our web site at  http://www.cbinet.com/events/HB492/index.html

2004 U.S. Pharma IT Compliance Workshops, November 15-19, Philadephia, PA
 
Five Day Workshop explaining how to satisfy the FDA requirements.  Featured topics include, Qualifying IT Networks and Infrastructure; The Immediate Impact of the FDA's NEW Guidance for industry on 21 CFR Part 11, Electronic Records and Electronic Signatures; Understanding and Applying Risk Management to Meet FDA Expectations for Computerized Systems; How to Design and Implement the Paperless Laboratory; Auditing Computerized Systems to PASS FDA Regulatory Inspections. For more info click on the link below:
http://www.rcwg.org/events


Bio-IT World Conference & Expo - May 17-19, 2005, Boston, MA
Bio-IT World Conference & Expo showcases the latest technology developments and research breakthroughs on the complete spectrum of topics involved in drug discovery through market delivery. Visit our web site at  http://www.bio-itworldexpo.com




Technology Watch

Recent releases and updates of compliance products


VelQuest   

SmartShell from VelQuest is said to provide 21 CFR Part 11 remediation for PC-based instruments and desktops that may not, by themselves, comply with the Part 11 regulations. It also provides centralized security and access control administration for all laboratory instruments, and a centralized repository for all regulated data.  In addition, SmartShell software provides these same capabilities for Microsoft's Excel and Word applications. VelQuest released its current application library showing 45 applications that have already been used in conjunction with its SmartShell compliance management system.


Agilent Technologies

Agilent's new method validation pack version A.02.01 for its ChemStation Plus chromatography data system (CDS) is the first system of its kind to provide solution stability calculations for short- and long-term stability studies as defined by the International Conference for Harmonization (ICH). The software further offers major productivity improvements for validation planning, execution, and reporting. Read the press release.


Datastream Systems

Datastream 7i, an asset performance management solution, has enhanced its Web-based capabilities and added stronger regulatory compliance features, including the addition of the entire Calibration Module to Datastream 7i Extended and the ability to apply auditing rules to custom fields and comments. This facilitates compliance and reduces the risk of costly violations for customers in regulated industries, such as pharmaceutical, oil and gas, and nuclear power. Read the product announcement.

 


Advertorial

The FDA Will Mandate SPL Use in 2005
Learn More with this Free White Paper

By Joe Jenkins
Marketing Director for Life Sciences, Arbortext

In today's complex, global life sciences marketplace, the ability to manage product information is a daunting task. Many departments across the enterprise use the approved product information for a variety of purposes, including package and labeling, promotional materials, and product web sites. It is common practice for each department to take a copy of the approved content and re-create it for its own use, leading to significant process inefficiencies and potential for inconsistent product information.

Additionally, there are many consumers of this product information including regulatory authorities, academic research centers, health care professionals, and the general public. These people depend and rely on accurate and consistent information about drug products independent of the manner in which they access this information, whether through paper-based, electronic, or other channels.

The ability to ensure greater control over this critical product information has led to the development of a standard for product labeling. This standard, known as Structured Product Labeling (SPL), is being adopted by the FDA to assist in greater patient safety and increased usability of product information across its consumer base.

In 2005, the FDA will mandate the use of Extensible Markup Language (XML) that is compliant with the SPL standard for electronic submissions. Arbortext has developed a free white paper about SPL to help companies:

·        Develop a deeper understanding of SPL

·        Discuss the goals and benefits of SPL

·        Understand the impact that SPL will have on current labeling processes

·        Identify additional resources for broadening SPL knowledge

The white paper provides a comprehensive overview of SPL, covering both business and technical topics. As such, this document is appropriate for anyone that has responsibility for labeling content within pharmaceutical and biotechnology companies, or other firms impacted by the FDA Guidance on Labeling Content.

To download this free white paper, An Introduction to Structured Product Labeling, please visit http://www.arbortext.com/spl_whitepaper.


This email was delivered to .

To subscribe to Regulatory Review, click here.


Published by Bio-IT World Copyright © 2004 Bio-IT World Inc./International Data Group. All rights reserved. All content copyright Bio-IT World Inc., 2004. All rights are reserved. No material may be reproduced electronically or in print without written permission from Bio-IT World Inc., One Speen Street, Framingham, MA 01701. For reprints and/or copyright permission, please contact RMS, 1808 Colonial Village Lane, Lancaster, PA; 17601 (717) 399-1900 ext. 172, or email: rwsmith@reprintbuyer.com.